BR112020006246A2 - Método para controle do peso de um sujeito em necessidade - Google Patents

Método para controle do peso de um sujeito em necessidade Download PDF

Info

Publication number
BR112020006246A2
BR112020006246A2 BR112020006246-4A BR112020006246A BR112020006246A2 BR 112020006246 A2 BR112020006246 A2 BR 112020006246A2 BR 112020006246 A BR112020006246 A BR 112020006246A BR 112020006246 A2 BR112020006246 A2 BR 112020006246A2
Authority
BR
Brazil
Prior art keywords
semagglutide
week
use according
fact
subject
Prior art date
Application number
BR112020006246-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Kabisch
Thomas Hansen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020006246(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of BR112020006246A2 publication Critical patent/BR112020006246A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112020006246-4A 2017-10-12 2018-10-10 Método para controle do peso de um sujeito em necessidade BR112020006246A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Publications (1)

Publication Number Publication Date
BR112020006246A2 true BR112020006246A2 (pt) 2021-03-30

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020006246-4A BR112020006246A2 (pt) 2017-10-12 2018-10-10 Método para controle do peso de um sujeito em necessidade

Country Status (18)

Country Link
US (4) US12029779B2 (https=)
EP (1) EP3694538A1 (https=)
JP (2) JP7148605B2 (https=)
KR (1) KR20200069316A (https=)
CN (4) CN119838000A (https=)
AU (2) AU2018348929B2 (https=)
BR (1) BR112020006246A2 (https=)
CA (1) CA3078652A1 (https=)
CL (1) CL2020000812A1 (https=)
IL (3) IL322969A (https=)
MA (1) MA50358A (https=)
MX (3) MX2020003049A (https=)
MY (1) MY204827A (https=)
PH (1) PH12020550185A1 (https=)
SG (1) SG11202002841PA (https=)
TW (1) TWI842681B (https=)
WO (1) WO2019072941A1 (https=)
ZA (3) ZA202503350B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078652A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
JP7761567B2 (ja) * 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022212271A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US12597496B2 (en) * 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
BR122019021416A2 (https=) 2003-09-19 2019-12-21
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
KR101438839B1 (ko) 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
CA2677852A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
PT2753312T (pt) 2011-09-08 2017-02-03 Mereo Biopharma 2 Ltd Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
EP2866825B1 (en) 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
KR102272671B1 (ko) * 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

Also Published As

Publication number Publication date
CN120241968A (zh) 2025-07-04
US20250235511A1 (en) 2025-07-24
ZA202503387B (en) 2025-09-25
TW201914611A (zh) 2019-04-16
TWI842681B (zh) 2024-05-21
EP3694538A1 (en) 2020-08-19
CN111212657A (zh) 2020-05-29
CA3078652A1 (en) 2019-04-18
US20240415935A1 (en) 2024-12-19
US20240316159A1 (en) 2024-09-26
RU2020114960A3 (https=) 2022-02-11
ZA202503350B (en) 2025-09-25
WO2019072941A1 (en) 2019-04-18
MY204827A (en) 2024-09-18
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
ZA202503388B (en) 2025-09-25
JP7475398B2 (ja) 2024-04-26
MX2020003049A (es) 2020-07-27
SG11202002841PA (en) 2020-04-29
CN119950682A (zh) 2025-05-09
CN119838000A (zh) 2025-04-18
MX2025002188A (es) 2025-04-02
IL322968A (en) 2025-10-01
US12029779B2 (en) 2024-07-09
IL322969A (en) 2025-10-01
AU2018348929A1 (en) 2020-05-07
JP2020536854A (ja) 2020-12-17
PH12020550185A1 (en) 2021-03-01
MA50358A (fr) 2020-08-19
JP2022132414A (ja) 2022-09-08
JP7148605B2 (ja) 2022-10-05
US12551536B2 (en) 2026-02-17
US12295988B2 (en) 2025-05-13
US20200237876A1 (en) 2020-07-30
RU2020114960A (ru) 2021-10-28
IL273470A (en) 2020-05-31
KR20200069316A (ko) 2020-06-16
AU2018348929B2 (en) 2025-02-27
MX2025002189A (es) 2025-04-02

Similar Documents

Publication Publication Date Title
BR112020006246A2 (pt) Método para controle do peso de um sujeito em necessidade
Ishii et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series
JP2020019790A (ja) プラダー・ウィリー症候群を治療する方法
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
Gusti et al. Effects of oxandrolone on lean body mass (Lbm) in severe burn patients: a randomized, double blind, placebo-controlled trial
BRPI0712051A2 (pt) combinação de análogos de somatostatina com antagonista de receptor do hormÈnio de crescimento ou dopamina
US20240277745A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
CN110636847A (zh) 用于预防及治疗肌肉疾病的组合物
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
Snehalatha et al. Metformin in prevention of type 2 diabetes
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
EP4146221A1 (en) Treatment of hyperuricemia
US20250170091A1 (en) Uses of selective androgen receptor modulator (sarm) compounds in chronic weight management
KR102246627B1 (ko) Ｈｍｂａ를 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물
RU2800651C2 (ru) Семаглутид в лекарственной терапии
US20260053769A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
US20250228804A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
Sanchetee et al. Diabetes and Cancer
De Ng et al. Pharmacological management update: clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024015864-7 PROTOCOLO 870240065542 EM 02/08/2024 11:45.O PEDIDO FOI DIVIDIDO NO BR122024015868-0 PROTOCOLO 870240065553 EM 02/08/2024 12:07.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.1 NA RPI NO 2824 DE 18/02/2025 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025013280-2 PROTOCOLO 870250053867 EM 26/06/2025 15:59.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]